Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v3.19.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
REVENUES:        
Product revenue $ 7,186,795 $ 4,194,602 $ 17,204,909 $ 12,821,741
License and other revenue 35,708 35,708 107,125 107,125
Total Revenues 7,222,503 4,230,310 17,312,034 12,928,866
OPERATING EXPENSES        
Cost of product revenue (exclusive of amortization expense shown below) 7,916,220 9,164,109 27,812,635 31,052,519
Research and development 491,404 1,002,818 1,879,025 3,008,816
Plasma center operating expenses 456,899 1,973,338 1,705,498 5,545,240
Amortization of intangibles 211,235 211,235 633,704 633,704
Selling, general and administrative 7,197,173 5,670,210 18,878,690 16,429,871
TOTAL OPERATING EXPENSES 16,272,931 18,021,710 50,909,552 56,670,150
LOSS FROM OPERATIONS (9,050,428) (13,791,400) (33,597,518) (43,741,284)
OTHER INCOME (EXPENSE):        
Interest and other income 281,896 75,581 619,103 135,197
Interest expense (2,649,404) (1,402,475) (6,262,489) (4,084,815)
Loss on extinguishment of debt 0 0 (9,962,495) 0
Gain on transfer of plasma center assets 0 0 11,527,421 0
Other expense (20,523) (17,191) (42,308) (14,556)
Other expense, net (2,388,031) (1,344,085) (4,120,768) (3,964,174)
NET LOSS $ (11,438,459) $ (15,135,485) $ (37,718,286) $ (47,705,458)
BASIC AND DILUTED LOSS PER COMMON SHARE $ (0.19) $ (0.33) $ (0.72) $ (1.06)
WEIGHTED AVERAGE SHARES OUTSTANDING, Basic and Diluted 59,317,830 46,350,392 52,673,190 44,796,986